Clinical trial NCT05354115: Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
Official title: Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Influenza A
Influenza Type B
Lead sponsor: Abbott Rapid Dx
Sponsor class: INDUSTRY
First posted: 2022-04-29
Enrollment: 676
Sex: ALL
Minimum age (years): 14
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal and nasopharyngeal swabs by the study sponsor, Abbott.

Detailed description: A minimum of 665 male and female Subjects will be prospectively enrolled at multiple clinical sites. A minimum of 90 Flu A reference positive subjects, a minimum of 90 Flu B reference positive subjects and a minimum of 100 SARS-CoV-2 reference positive subjects will be enrolled. In addition, a minimum of 385 reference-negative subjects will be enrolled. In order to meet these minimum numbers it is anticipated that approximately 2000 subjects will be enrolled in total.

Subjects should be enrolled from point of care for this study. After informed consent has been obtained, operators will collect one nasal swab from both nostrils from each Subject. Every second subject will be asked to blow their nose first and this will be recorded.

Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril.

The collected swab will be returned to a plastic tube (provided by the sponsor) and immediately (or within 15 minutes of collection) stored frozen at -80°C (or -20°C if -80°C storage is not available) for later testing with the Panbio™ Rapid Panel. Touching of the tube wall with the swab should be avoided. Nasal samples must be collected prior to the Nasopharyngeal sampling.

After the nasal sampling, the operators will collect a nasopharyngeal swab from one nostril of each subject. The NP swab will be returned to a plastic tube (provided by the sponsor) by study staff (touching the tube walls should be avoided) and immediately (or within 15 minutes of collection) stored frozen at -80°C (or -20°C if -80°C storage is not available) for later testing with the Panbio™ Rapid Panel.

A second nasopharyngeal swab, collected from the other nostril of each subject will be eluted in Universal Transport Media (UTM) and used for testing with RT-PCR protocols for Flu A, Flu B and SARS-CoV-2 as per local procedures. The remaining UTM will be labelled with Subject ID and immediately stored frozen at -80°C (or -20°C minimum). The RT-PCR methods used must have CE marking or FDA approval, with COVID-19 and Flu assay clearance for nasopharyngeal specimens and must be approved by the Sponsor. Nasopharyngeal sampling should be performed by trained healthcare professionals who routinely conduct nasopharyngeal sampling as part of their other standard of care and clinical duties.

All other aspects of the Subject's care will remain the same with no deviation from prescribed practice.

Each subject's demographic information, symptomology data, and professionally performed test result and questionnaire will be recorded on source documentation and transferred to an Electronic Data Capture system.

Samples collected in this study will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel by the study sponsor, Abbott.

Eligibility criteria: Inclusion Criteria:

* Subjects \>14 years of age who are able and willing to provide written informed consent, and deemed suitable for nasopharyngeal sampling in accordance with local procedures, suspected of having a respiratory viral infection consistent with COVID-19 and/or Flu by their healthcare provider within the first five days of the onset of symptoms, and presenting at least two of the following symptoms: fever, headache, extreme tiredness, dry cough, sore throat, runny or stuffy nose, muscle aches, loss of smell, loss of taste or shortness of breath, will be prospectively enrolled.

Exclusion Criteria:

* • Subject has had a nasal or a nasopharyngeal swab taken within the last 4 hours.

  * Subject has active nose bleeds or acute facial injuries/trauma
  * Subject has received a nasal vaccine (i.e., FluMist®) within the previous five (5) days.
  * Subject is currently taking or has taken an antiviral medication-i.e., Amantadine, Rimantadine, Relenza® (Zanamivir), Tamiflu® (Oseltamivir Phosphate), and Flumadine®-for influenza within the previous thirty (30) days.
  * Subject is currently enrolled in a study to evaluate an investigational drug.
  * Subject is unwilling or unable to provide informed consent.
  * Vulnerable populations as deemed inappropriate for study by the site's PI and/or reviewing REC.

Primary outcomes:
measure: Nasal and Nasopharyngeal Sample Collection
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Easley
country: United States
facility: Urgent Care Clinical Trials Easley
state: South Carolina
Study officials:
References: